Abstract
Zusammenfassung. Funktionelle Magen-Darm-Beschwerden sind in der Allgemeinbevölkerung weit verbreitet, und das Reizdarmsyndrom (Irritable Bowel Syndrome, IBS) ist eines der häufigsten gastroenterologischen Krankheitsbilder. Trotz individuell sehr unterschiedlicher klinischer Präsentation berichtet ein Grossteil der Patienten über eine Abhängigkeit ihrer Beschwerden von der Nahrungsaufnahme bzw. von bestimmten Nahrungsmitteln. Die FODMAP-arme Diät, durch eine spezialisierte Ernährungsberatung instruiert, zeigt sich sehr wirksam zur Symptomreduktion bei IBS-Patienten. Sie basiert auf einer Reduktion fermentierbarer Kohlenhydrate. Ziel der Diät ist es, potenzielle nutritive Auslöser abdominaler Symptome zu identifizieren und diese in der täglichen Ernährung zu meiden.
Abstract. Functional gastrointestinal disorders are common in the general population, and irritable bowel syndrome (IBS) is one of the most common gastrointestinal disorders. Although symptom presentation varies widely between individuals, most patients report an association between gastrointestinal symptoms and intake of foods in general or specific food products. The low FODMAP diet, delivered by a professional nutritionist, has been shown to reduce abdominal symptoms in IBS patients. The diet is based on the reduction of fermentable carbohydrates in patients’ diet with the aim to identify potential nutritive triggers for abdominal symptoms.
Bibliografie
, : The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects. Aliment Pharmacol Ther 2003; 17: 643–650.
: Irritable bowel syndrome and dyspepsia in the general population: overlap and lack of stability over time. Gastroenterology 1995; 109: 671–680.
: Health-related quality of life, work productivity, and health care resource utilization of subjects with irritable bowel syndrome: baseline results from LOGIC (Longitudinal Outcomes Study of Gastrointestinal Symptoms in Canada), a naturalistic study. Clin Ther 2006; 28: 1726–1735; discussion 10–11.
: Epidemiology and quality of life in functional gastrointestinal disorders. Aliment Pharmacol Ther 2004; 20(Suppl 7): 31–39.
: Functional bowel disorders. Gastroenterology 2006; 130: 1480–1491.
. Irritable bowel syndrome – an evidence-based approach to diagnosis. Aliment Pharmacol Ther 2004; 19: 1235–1245.
: «Red flag» evaluation yield in irritable bowel syndrome. J Gastrointestin Liver Dis 2012; 21: 153–156.
: Breath testing to evaluate lactose intolerance in irritable bowel syndrome correlates with lactulose testing and may not reflect true lactose malabsorption. Am J Gastroenterol 2003; 98: 2700–2704.
, .: Positive or negative fructose breath test results do not predict response to fructose restricted diet in children with recurrent abdominal pain: results from a prospective randomized trial. Klin Padiatr 2014; 226: 268–273.
: Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. A double-blind, randomized, placebo-controlled study. Am J Gastroenterol 2003; 98: 412–419.
, .: A combined nutrient and lactulose challenge test allows symptom-based clustering of patients with irritable bowel syndrome. Am J Gastroenterol 2013; 108: 786–795.
: Food: the forgotten factor in the irritable bowel syndrome. Gastroenterol Clin North Am 2011; 40: 141–162.
: Rifaximin treatment for the irritable bowel syndrome with a positive lactulose hydrogen breath test improves symptoms for at least 3 months. Aliment Pharmacol Ther 2012; 36: 1084–1093.
: Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol 2000; 95: 3503–3506.
: The evidence base for efficacy of the low FODMAP diet in irritable bowel syndrome: is it ready for prime time as a first-line therapy?J Gastroenterol Hepatol 2017; 32(Suppl 1): 32–35.
, : A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology 2014; 146: 67–75.e5.
, : Bowel Disorders. Gastroenterology 2016; 150: 1393–1407.
, : Food-related gastrointestinal symptoms in the irritable bowel syndrome. Digestion 2001; 63: 108–115.
: Perceived food intolerance in subjects with irritable bowel syndrome – etiology, prevalence and consequences. Eur J Clin Nutr 2006; 60: 667–672.
: How do FODMAPs work?J Gastroenterol Hepatol 2017; 32 (Suppl 1): 36–39.
: Short-chain carbohydrates and functional gastrointestinal disorders. Am J Gastroenterol 2013; 108: 707–717.
, : Differential effects of FODMAPs (fermentable oligo-, di-, mono-saccharides and polyols) on small and large intestinal contents in healthy subjects shown by MRI. Am J Gastroenterol 2014; 109: 110–119.
, : The low FODMAP diet improves gastrointestinal symptoms in patients with irritable bowel syndrome: a prospective study. Int J Clin Pract 2013; 67: 895–903.
: Human gut bacterial communities are altered by addition of cruciferous vegetables to a controlled fruit- and vegetable-free diet. J Nutr 2009; 139: 1685–1691.
, : Fructooligosaccharides and fiber partially prevent the alterations in fecal microbiota and short-chain fatty acid concentrations caused by standard enteral formula in healthy humans. J Nutr 2005; 135: 1896–1902.
, : Selective stimulation of bifidobacteria in the human colon by oligofructose and inulin. Gastroenterology 1995; 108: 975–982.
, : Effect of inulin on the human gut microbiota: stimulation of Bifidobacterium adolescentis and Faecalibacterium prausnitzii. Br J Nutr 2009; 101: 541–550.
, : Effects of a gluten-free diet on gut microbiota and immune function in healthy adult human subjects. Br J Nutr 2009; 102: 1154–1160.
, : Fermentable carbohydrate restriction reduces luminal bifidobacteria and gastrointestinal symptoms in patients with irritable bowel syndrome. J Nutr 2012; 142: 1510–1518.
: Intestinal microbiota in health and disease: role of bifidobacteria in gut homeostasis. World J Gastroenterol 2014; 20: 15163–15176.
: Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome. Gastroenterology 2011; 141: 1792–1801.
, : Intestinal microbiota in healthy adults: temporal analysis reveals individual and common core and relation to intestinal symptoms. PloS One 2011; 6: e23035.
, : Fecal fermentation in irritable bowel syndrome: Influence of dietary restriction of fermentable oligosaccharides, disaccharides, monosaccharides and polyols. Digestion 2016; 94: 50–56.
: Review article: short chain fatty acids in health and disease. Aliment Pharmacol Ther 1998; 12: 499–507.
, : Colonic health: fermentation and short chain fatty acids. J Clin Gastroenterol 2006; 40: 235–243.
, : The effects of butyrate enemas on visceral perception in healthy volunteers. Neurogastroenterol Motil 2009; 21: 952–e76.
, : Diets that differ in their FODMAP content alter the colonic luminal microenvironment. Gut 2015; 64: 93–100.
, : Effects of varying dietary content of fermentable short-chain carbohydrates on symptoms, fecal microenvironment, and cytokine profiles in patients with irritable bowel syndrome. Neurogastroenterol Motil 2017; 29.
, : FODMAPs alter symptoms and the metabolome of patients with IBS: a randomised controlled trial. Gut 2016; 4.
, : Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 2004; 126: 693–702.
, : Histamine receptor H1-mediated sensitization of TRPV1 mediates visceral hypersensitivity and symptoms in patients with irritable bowel syndrome. Gastroenterology 2016; 150: 875–887.e9.
, : The alteration of enterochromaffin cell, mast cell, and lamina propria T lymphocyte numbers in irritable bowel syndrome and its relationship with psychological factors. J Gastroenterol Hepatol 2008; 23: 1689–1694.
, : Subclinical mucosal inflammation in diarrhea-predominant irritable bowel syndrome (IBS) in a tropical setting. Scand J Gastroenterol 2012; 47: 619–624.
: Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome. Pain 2009; 146: 41–46.
: Re-challenging FODMAPs: the low FODMAP diet phase two. J Gastroenterol Hepatol 2017; 32(Suppl 1): 11–15.
, : Diet low in FODMAPs reduces symptoms of irritable bowel syndrome as well as traditional dietary advice: a randomized controlled trial. Gastroenterology 2015; 149: 1399–1407.e2.
: A randomized controlled trial comparing the low FODMAP det vs. modified NICE guidelines in US adults with IBS-D. Am J Gastroenterol 2016; 111: 1824–1832.
: Low FODMAP in 2017: Lessons learned from clinical trials and mechanistic studies. Neurogastroenterol Motil 2017; 29.
, : The Low FODMAP Diet: Many Question Marks for a Catchy Acronym. Nutrients 2017; 9: pii: E292.
, : Long-term success of GUT-directed group hypnosis for patients with refractory irritable bowel syndrome: a randomized controlled trial. Am J Gastroenterol 2013; 108: 602–609.
, : Randomised clinical trial: the efficacy of gut-directed hypnotherapy is similar to that of the low FODMAP diet for the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2016; 44: 447–459.
: Controlled trial of hypnotherapy in the treatment of severe refractory irritable-bowel syndrome. Lancet 1984; 2: 1232–1234.
, : Effects of gut-directed hypnotherapy on IBS in different clinical settings-results from two randomized, controlled trials. Am J Gastroenterol 2012; 107: 276–285.
, : Depression and somatization are associated with increased postprandial symptoms in patients with irritable bowel syndrome. Gastroenterology 2016; 150: 866–874.
, : Physical and psychological co-morbidity in irritable bowel syndrome: a matched cohort study using the General Practice Research Database. Aliment Pharmacol Ther 2006; 24: 879–886.
, : Association of participation in a mindfulness programme with bowel symptoms, gastrointestinal symptom-specific anxiety and quality of life. Aliment Pharmacol Ther 2011; 34: 363–373.
, : Mindfulness-based stress reduction for the treatment of irritable bowel syndrome symptoms: a randomized wait-list controlled trial. Int J Behav Med 2013; 20: 385–396.
, : Comparison of symptom response following advice for a diet low in fermentable carbohydrates (FODMAPs) versus standard dietary advice in patients with irritable bowel syndrome. J Hum Nutr Diet 2011; 24: 487–495.
: Sensitivity to wheat, gluten and FODMAPs in IBS: facts or fiction?Gut 2015; 65: 169–178.
